A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT02247531 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

975

Enrollment

INDUSTRY

Sponsor class

Conditions

Geographic Atrophy

Interventions

DRUG: Lampalizumab
OTHER: Sham Comparator

Sponsor

Hoffmann-La Roche